GlassScriptPhysician profile
Roger J Klein
NPI 1205947868
$4,585.97
in general payments reported to CMS, 2019-2025
29 companies · $694 in 2025
The $694 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $378 · 2021: $887 · 2022: $653 · 2023: $806 · 2024: $675 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,358.39 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $754.63 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $639.76 | 2019-2022 | |
| Pfizer INC. | $611.49 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.63 | 2020-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $127.77 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $116.27 | 2019-2023 | Repatha |
| Abbott Laboratories | $107.62 | 2021-2024 | Cardiomems, Confirm Rx |
| Boston Scientific Corporation | $62.57 | 2022-2024 | Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $61.91 | 2023-2025 | |
| Novo Nordisk INC | $58.84 | 2024-2025 | Wegovy, Ozempic |
| Merck Sharp & Dohme LLC | $52.00 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $49.24 | 2019 | |
| Medtronic Vascular, INC. | $47.51 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $42.32 | 2024 | Arcalyst |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $34.72 | 2021-2023 | Injectafer |
| Cvrx, INC. | $28.33 | 2023-2024 | Barostim Neo System |
| Abbvie INC. | $26.05 | 2021 | |
| Inspire Medical Systems, INC. | $24.87 | 2025 | Inspire |
| Atricure, INC. | $24.58 | 2024 | |
| Esperion Therapeutics, INC. | $20.98 | 2021 | |
| Vifor Pharma, INC. | $20.43 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.55 | 2025 | Caplyta |
| Regeneron Healthcare Solutions, INC. | $15.55 | 2023 | Evkeeza |
| Zoll Circulation INC | $14.65 | 2023 | Therox Ds2 Console, Downstream Cartridge, Catheter |
| Lundbeck LLC | $13.98 | 2020 | |
| Philips North America LLC | $13.51 | 2023 | |
| Kestra Medical Technology Services, INC. | $13.37 | 2023 | Assure Wcd |
| Lilly USA, LLC | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.